Reversal	reversal	O	O
of	of	O	O
neuroleptic-induced	neuroleptic-induced	O	O
catalepsy	catalepsy	O	S_disease
by	by	O	O
novel	novel	O	O
aryl-piperazine	aryl-piperazine	O	O
anxiolytic	anxiolytic	S_chemicals	O
drugs	drugs	S_chemicals	O
.	.	O	O

The	the	O	O
novel	novel	O	O
anxiolytic	anxiolytic	S_chemicals	O
drug	drug	S_chemicals	O
,	,	O	O
buspirone	buspirone	S_chemicals	O
,	,	O	O
reverses	reverses	O	O
catalepsy	catalepsy	O	S_disease
induced	induced	O	O
by	by	O	O
haloperidol	haloperidol	O	O
.	.	O	O

A	a	O	O
series	series	O	O
of	of	O	O
aryl-piperazine	aryl-piperazine	O	O
analogues	analogues	O	O
of	of	O	O
buspirone	buspirone	S_chemicals	O
and	and	O	O
other	other	O	O
5-hydroxytryptaminergic	5-hydroxytryptaminergic	O	O
agonists	agonists	O	O
were	were	O	O
tested	tested	O	O
for	for	O	O
their	their	O	O
ability	ability	O	O
to	to	O	O
reverse	reverse	O	O
haloperidol	haloperidol	O	O
induced	induced	O	O
catalepsy	catalepsy	O	S_disease
.	.	O	O

Those	those	O	O
drugs	drugs	S_chemicals	O
with	with	O	O
strong	strong	O	O
affinity	affinity	O	O
for	for	O	O
5-hydroxytryptamine1a	5-hydroxytryptamine1a	O	O
receptors	receptors	O	O
were	were	O	O
able	able	O	O
to	to	O	O
reverse	reverse	O	O
catalepsy	catalepsy	O	S_disease
.	.	O	O

Drugs	drugs	S_chemicals	O
with	with	O	O
affinity	affinity	O	O
for	for	O	O
other	other	O	O
5-HT	5-ht	O	O
receptors	receptors	O	O
or	or	O	O
weak	weak	O	O
affinity	affinity	O	O
were	were	O	O
ineffective	ineffective	O	O
.	.	O	O

However	however	O	O
,	,	O	O
inhibition	inhibition	O	O
of	of	O	O
postsynaptic	postsynaptic	O	S_disease
5-HT	5-ht	O	O
receptors	receptors	O	O
neither	neither	O	O
inhibited	inhibited	O	O
nor	nor	O	O
potentiated	potentiated	O	O
reversal	reversal	O	O
of	of	O	O
catalepsy	catalepsy	O	S_disease
and	and	O	O
leaves	leaves	O	O
open	open	O	O
the	the	O	O
question	question	O	O
as	as	O	O
to	to	O	O
the	the	O	O
site	site	O	O
or	or	O	O
mechanism	mechanism	O	O
for	for	O	O
this	this	O	O
effect	effect	O	O
.	.	O	O

